Fig. 4: Loss of UBE2O reduces tumor growth and enhances radiosensitivity in lung cancer in vitro and in vivo.

a Upper panel: cell lysates were analyzed by immunoblotting with anti-UBE2O antibody. Lower panel: quantification of UBE2O band intensity was shown (n = 3). b H1299 cells stably expressing sh-Control or sh-UBE2O were collected and examined the knockdown efficiency of UBE2O by western blotting (n = 3). c Nude mice were subcutaneously injected with H1299 cells stably expressing sh-Control or sh-UBE2O. The tumor volumes were measured every 3 days (n = 4 mice/group). Data were shown as mean ± SEM. **P < 0.01. d Left panel: representative images of the comet tail. Scale bar, 50 μm. Right panel: quantification of the olive tail moment in each group were shown (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001. e Left panel: representative immunostaining images of Rad51 foci. A cell containing 10 or more foci was considered as a foci-positive cell. Scale bar, 10 μm. Right panel: the percentage of Rad51 foci-positive cells in each group were shown (n = 3). **P < 0.01, ***P < 0.001. f H1299 and A549 cells were transfected with indicated siRNAs and irradiated at different doses as indicated respectively. After 14 days, cell colonies were fixed and counted, and the survival fraction was calculated (n = 3). **P < 0.01, ***P < 0.001. g The growth curves of the xenograft tumors for each group are represented. H1299 cells stably expressing sh-Control or sh-UBE2O were subcutaneously injected in the right hind limb of nude mice, respectively. The mice were irradiated with 10 Gy when the tumor volume reached 100 mm³. Data were shown as mean ± SEM (n = 5 mice/group). *P < 0.05, **P < 0.01.